JANUX THERAPEUTICS INC (JANX)
US47103J1051 - Common Stock
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
/CNW/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the...
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
/PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of...
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Janux Therapeutics (NASDAQ:JANX) just reported results for the first quarter of...
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Janux Therapeutics (JANX) stock has gone parabolic: what next?
Janux Therapeutics (NASDAQ: JANX) stock price has gone vertical this year, making it one of the top-performing biotech companies in Wall Street. It jumped to a high of $61 on Monday about 975% above the lowest point in 2023, giving it a market cap of over $2.45 billion. Analysts are optimistic about Janux Janux Therapeutics […]
Take the Money and Run: 3 Overbought Stocks to Sell ASAP
Although speculators were smart enough to jump on these ideas, they’re currently overbought stocks that may require trimming.
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank?
Why Janux Therapeutics Stock Is Crushing It This Week
Janux's silence about a potential acquisition deal could be golden.
Noteworthy Thursday Option Activity: JANX, WFC, AMD
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options.
Why Janux Therapeutics Stock Soared as the Market Sagged Today
One of the hotter biotech companies on the scene might be changing owners before long.
Cancer-Drug Maker Janux Therapeutics Weighs Possible Sale
Drugmaker Janux Therapeutics Inc. is exploring options, including a potential sale, after receiving takeover interest from larger pharmaceutical companies, people with knowledge of the matter said.
Commit To Purchase Janux Therapeutics At $25, Earn 26.5% Annualized Using Options
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Janux Therapeutics (NASDAQ:JANX) just reported results for the fourth quarter o...
2 Stocks That Have More Than Tripled This Year: Are They Buys?
Don't jump on the bandwaggon too quickly.
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?
The biotech tantalized investors with a very promising data update.
Janux Therapeutics prices stock and warrants offering to raise $296.5M (NASDAQ:JANX)
Janux Therapeutics (NASDAQ:JANX) said Thursday it has priced an underwritten public offering to raise $296.5 million.
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?
The company reported in-line sales for the fourth quarter, but shares soared by double digits.
Janux Therapeutics looks to raise capital through public offering (NASDAQ:JANX)
Janux Therapeutics announces a $175M underwritten public offering of common stock, with a possible additional $26.25M for underwriters.
